| Cancer stem cell immunology: key to understanding tumorigenesis and tumor immune escape? VS Bruttel, J Wischhusen Frontiers in immunology 5, 360, 2014 | 200 | 2014 |
| The cancer stem cell subtype determines immune infiltration of glioblastoma CP Beier, P Kumar, K Meyer, P Leukel, V Bruttel, I Aschenbrenner, ... Stem cells and development 21 (15), 2753-2761, 2012 | 92 | 2012 |
| Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1) J Diessner, V Bruttel, RG Stein, E Horn, SFM Häusler, J Dietl, A Hönig, ... Cell death & disease 5 (3), e1149-e1149, 2014 | 72 | 2014 |
| Neurodegeneration by α-synuclein-specific T cells in AAV-A53T-α-synuclein Parkinson’s disease mice AA Karikari, RL McFleder, E Ribechini, R Blum, V Bruttel, S Knorr, ... Brain, behavior, and immunity 101, 194-210, 2022 | 48 | 2022 |
| Targeting breast cancer stem cells with HER2-specific antibodies and natural killer cells J Diessner, V Bruttel, K Becker, M Pawlik, R Stein, S Häusler, J Dietl, ... American journal of cancer research 3 (2), 211, 2013 | 38 | 2013 |
| Human parthenogenetic embryonic stem cell-derived neural stem cells express HLA-G and show unique resistance to NK cell-mediated killing J Schmitt, S Eckardt, PG Schlegel, AL Sirén, VS Bruttel, KJ McLaughlin, ... Molecular Medicine 21, 185-196, 2015 | 22 | 2015 |
| Cancer stem cell immunology: key to understanding tumorigenesis and tumor immune escape? Front Immunol. 2014; 5: 360 VS Bruttel, J Wischhusen Epub 2014/08/15. doi: 10.3389/fimmu. 2014. 00360 PMID: 25120546, 2014 | 10 | 2014 |
| Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulation V Bruttel, J Wischhusen US Patent App. 18/329,267, 2023 | | 2023 |
| alpha-synuclein peptides presented on chimeric MHC class Ib molecules prevent loss of substantia nigra neurons in an animal model for Parkinson’s disease J Wischhusen, J Wu, F Ahsan, MF Rhonda, AK Karl, SM Jayaram, ... The Journal of Immunology 208 (1_Supplement), 60.16-60.16, 2022 | | 2022 |
| Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulation V Bruttel, J rg WISCHHUSEN | | 2020 |
| Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulation V BRUTTEL, J WISCHHUSEN | | 2018 |
| Soluble HLA-G binds to dendritic cells which likely suppresses anti-tumour immune responses in regional lymph nodes in ovarian carcinoma VS Bruttel Universität Würzburg, 2015 | | 2015 |
| Therapie von Brustkrebsstammzellen beim HER2 positiven Mammakarzinom mit HER2 spezifischen Antikörpern (T-DM1 und Pertuzumab) A Hönig, F Reim, M Junker, V Bruttel, A Chandran, I Montalban, J Dietl, ... Geburtshilfe und Frauenheilkunde 71 (08), V_14, 2011 | | 2011 |
| Therapie von Brustkrebstammzellen beim HER2 positiven Mammakarzinom mit HER2 spezifischen Antikörpern (T-DM1 und Pertuzumab) J Diessner, F Reim, M Junker, V Bruttel, A Chandran, I Montalban, J Dietl, ... Geburtshilfe und Frauenheilkunde 71 (05), P221, 2011 | | 2011 |
| Hemmung der Induktion von Tumorstammzellen J Diessner, F Reim, M Junker, V Bruttel, A Chandran, I Montalban, J Dietl, ... Geburtshilfe und Frauenheilkunde 71 (05), P321, 2011 | | 2011 |
| The Relevance of Phosphorylated YB-1 for Multiple Myeloma Cell Survival and Drug Resistance M Effenberger, V Bruttel, RC Bargou, K Bommert Blood, The Journal of the American Society of Hematology 112 (11), 734-734, 2008 | | 2008 |
